ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00136799
Recruitment Status : Completed
First Posted : August 29, 2005
Last Update Posted : February 23, 2017
Sponsor:
Information provided by (Responsible Party):
Novartis

August 25, 2005
August 29, 2005
February 23, 2017
June 2005
April 2006   (Final data collection date for primary outcome measure)
Percent change from baseline in low density lipoprotein cholesterol after 12 weeks
Not Provided
Complete list of historical versions of study NCT00136799 on ClinicalTrials.gov Archive Site
  • Percent change from baseline in total cholesterol after 12 weeks
  • Percent change from baseline in high density lipoprotein cholesterol after 12 weeks
  • Percent change from baseline in total triglycerides after 12 weeks
Not Provided
Not Provided
Not Provided
 
Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia
Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia
The purpose of the study is to evaluate the safety and tolerability of fluvastatin 80 mg in a Chinese population. This study is not recruiting patients in the US.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
  • Mixed Dyslipidemia
  • Hypercholesterolemia
Drug: Fluvastatin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
325
Not Provided
April 2006
April 2006   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Mixed dyslipidemia
  • Primary hypercholesterolemia

Exclusion Criteria:

  • Pregnant or lactating women
  • Age > 18 years

Other protocol-defined inclusion and exclusion criteria may apply.

Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
China
 
 
NCT00136799
CXUO320B2302
Not Provided
Not Provided
Not Provided
Novartis
Novartis
Not Provided
Study Director: Novartis Novartis Pharmaceuticals
Novartis
February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP